Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Humana reports before the market open, meaning Day 0 captures the first full trading session where investors react to results, while Day +1 reflects follow-through sentiment.

Humana's post-earnings price action has been volatile, with an average absolute Day 0 move of 5.18% and Day +1 follow-through averaging 2.66%. The most recent report (Q2 2026, July 29) saw the stock drop 5.99% on Day 0 despite beating estimates, reflecting investor disappointment that management didn't raise full-year guidance even as peers were hiking their outlooks. The Day +1 move was a modest 0.34% gain, suggesting the initial selloff was largely contained.

The largest Day 0 reaction came in July 2025, when the stock surged 12.40% following a strong earnings beat, though it gave back 4.44% the following session. Conversely, the November 2025 report triggered a 6.01% Day 0 decline followed by an additional 5.22% drop on Day +1, one of the few instances where negative momentum extended into the second session.

The Day 0 range—measuring the full intraday swing from high to low—has averaged 8.95%, indicating significant intraday volatility regardless of the directional close. This suggests that initial reactions can be sharp in either direction before the market settles on a consensus view. The Day +1 range of 4.75% shows that volatility typically moderates but remains elevated compared to normal trading.

Part 2.2: Options Market Expected Move

The options market is pricing a 5.54% expected move for this week's expiration, which sits slightly above the 5.18% average historical Day 0 move but well below some of the more extreme reactions Humana has experienced. The expected move implies a trading range between $388.87 and $434.45, suggesting options traders are anticipating a meaningful but not outsized reaction to the results.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on Humana, with a consensus rating of 4.12 out of 5.0 (Strong Buy). The breakdown shows 15 Strong Buys, 1 Moderate Buy, 9 Holds, and 1 Strong Sell among 26 analysts covering the stock.

Sentiment has improved over the past month, with the average recommendation rising from 3.92 to 4.12. The number of Strong Buy ratings increased from 13 to 15, while Hold ratings declined from 12 to 9, indicating growing confidence among the analyst community.

The average price target of $463.12 implies 12.5% upside from the current price of $411.79. The range of targets is wide, spanning from a low of $280.00 to a high of $596.00, reflecting divergent views on the company's ability to execute its margin recovery strategy. The high target suggests some analysts see substantial upside if Humana successfully navigates its profitability challenges and benefits from the dramatic improvement in 2027 star ratings.

The recent improvement in analyst sentiment appears tied to the October announcement of Humana's star ratings recovery for 2027, with 95% of members now in 4-star-or-higher plans compared to just 20% for 2026. This turnaround is expected to restore billions in bonus payments and improve the company's competitive positioning. However, the wide dispersion in price targets reflects ongoing uncertainty about near-term medical cost trends and the execution risk around the company's plan to exit lower-return products while retaining profitable membership.

Part 4: Technical Picture

Humana's technical setup heading into earnings shows a stock that has built substantial momentum over the past year but is encountering near-term resistance. The Barchart Technical Opinion stands at 88% Buy, down slightly from 100% Buy a week ago and 96% Buy a month ago, suggesting some recent softness but still reflecting a strongly bullish overall signal.

Timeframe Analysis:

• Short-term (50% Buy): The moderate buy signal indicates near-term momentum has cooled, consistent with the stock trading below its 5-day, 10-day, and 20-day moving averages
• Medium-term (100% Buy): Strong buy signal suggests the intermediate trend remains firmly positive, supported by the stock's position above key longer-term averages
• Long-term (100% Buy): Strong buy signal reflects the stock's powerful uptrend over the past year, with the price well above the 200-day moving average

Trend Characteristics: The signal strength is rated as "Good" with "Average" direction, indicating a solid technical foundation but without the explosive momentum that would characterize an exceptional setup. This suggests the stock is in a healthy uptrend but may be consolidating recent gains rather than breaking out to new highs.

The stock is trading at $411.79, positioned above the 50-day ($403.25), 100-day ($393.64), and 200-day ($311.15) moving averages, confirming the longer-term uptrend remains intact. However, the price sits below the 5-day ($414.40), 10-day ($415.56), and 20-day ($420.14) averages, indicating recent weakness and suggesting the stock has pulled back from recent highs.

The 32% gain above the 200-day moving average underscores the strength of the rally over the past year, but the failure to hold above short-term averages suggests some profit-taking or caution ahead of earnings. The technical setup is neither strongly supportive nor cautionary—the stock has room to move in either direction depending on the results and guidance. A beat-and-raise scenario could propel the stock back above near-term resistance at the 20-day average, while a disappointment could test support at the 50-day moving average around $403.